PREVALENCE SCREENING FOR OVARIAN-CANCER IN POSTMENOPAUSAL WOMEN BY CA 125 MEASUREMENT AND ULTRASONOGRAPHY

被引:282
作者
JACOBS, I
DAVIES, AP
BRIDGES, J
STABILE, I
FAY, T
LOWER, A
GRUDZINSKAS, JG
ORAM, D
机构
[1] ROYAL LONDON HOSP, ACAD UNIT OBSTET & GYNAECOL, LONDON E1 1BB, ENGLAND
[2] ROYAL LONDON HOSP, GYNAECOL ONCOL UNIT, LONDON E1 1BB, ENGLAND
来源
BRITISH MEDICAL JOURNAL | 1993年 / 306卷 / 6884期
关键词
D O I
10.1136/bmj.306.6884.1030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-To assess the performance of the sequential combination of serum CA 125 measurement and ultrasonography in screening for ovarian cancer. Design-The serum CA 125 concentration of each subject was determined and those with a concentration greater-than-or-equal-to 30 U/ml were recalled for abdominal ultrasonography. If ultrasonography gave abnormal results surgical investigation was arranged. Volunteers were followed up by annual postal questionnaire. Setting-General practice, occupational health departments, ovarian cancer screening clinic. Subjects-22 000 women volunteers who were postmenopausal and aged over 45 years. Main outcome measures-Apparent sensitivity, specificity, positive predictive value, years of cancer detected. Results-41 women had a positive screening result and were investigated surgically. 11 had ovarian cancer (true positive result) and 30 had other disorders or no abnormality (false positive result). Of the 21959 volunteers with a negative screening result, eight subsequently presented clinically with ovarian cancer (false negative result) and 21951 had not developed ovarian cancer during follow up (apparent true negative result). The screening protocol achieved a specificity of 99.9%, a positive predictive value of 26.8%, and an apparent sensitivity of 78.6% and 57.9% at one year and two year follow up respectively. The estimated number of years of cancer detected by the prevalence screen was 1.4 years. Conclusions-This screening protocol is highly specific for ovarian cancer and can detect a substantial proportion of cases at a preclinical stage. Further investigation is required to determine the effect of the screening protocol on the ratio of early to late stage disease detected and on mortality from ovarian cancer.
引用
收藏
页码:1030 / 1034
页数:5
相关论文
共 25 条
[1]  
ANNEGERS JF, 1979, CANCER, V43, P723, DOI 10.1002/1097-0142(197902)43:2<723::AID-CNCR2820430248>3.0.CO
[2]  
2-1
[3]  
BAST RC, 1991, CANCER-AM CANCER SOC, V68, P1758, DOI 10.1002/1097-0142(19911015)68:8<1758::AID-CNCR2820680819>3.0.CO
[4]  
2-#
[5]   REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].
BAST, RC ;
FEENEY, M ;
LAZARUS, H ;
NADLER, LM ;
COLVIN, RB ;
KNAPP, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337
[6]  
BAST RC, 1983, NEW ENGL J MED, V309, P169
[7]   TRANS-VAGINAL COLOR FLOW IMAGING - A POSSIBLE NEW SCREENING TECHNIQUE FOR OVARIAN-CANCER [J].
BOURNE, T ;
CAMPBELL, S ;
STEER, C ;
WHITEHEAD, MI ;
COLLINS, WP .
BRITISH MEDICAL JOURNAL, 1989, 299 (6712) :1367-1370
[8]  
CAMPBELL S, 1982, LANCET, V1, P425
[9]   TRANS-ABDOMINAL ULTRASOUND SCREENING FOR EARLY OVARIAN-CANCER [J].
CAMPBELL, S ;
BHAN, V ;
ROYSTON, P ;
WHITEHEAD, MI ;
COLLINS, WP .
BMJ-BRITISH MEDICAL JOURNAL, 1989, 299 (6712) :1363-1367
[10]   URINARY GONADOTROPIN FRAGMENT, A NEW TUMOR-MARKER .2. DIFFERENTIATING A BENIGN FROM A MALIGNANT PELVIC MASS [J].
COLE, LA ;
NAM, JH ;
CHAMBERS, JT ;
SCHWARTZ, PE .
GYNECOLOGIC ONCOLOGY, 1990, 36 (03) :391-394